Cesca Therapeutics Announces Issuance Of New U.S. Patent
RANCHO CORDOVA, Calif., June 23, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics, Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced the issuance of U.S. Patent No. 9,050,422 by the U.S. Patent and Trademark Office. The patent for "Stem and Progenitor Cell Compositions Recovered from Bone Marrow or Cord Blood" is a divisional for U.S. Patent No. 8,167,139 and has claims to the compositions of stem cells recovered from bone marrow and cord blood and the respective device and methods to achieve those compositions.
Kenneth L. Harris, President of Cesca Therapeutics stated, "We are pleased to have received this very significant patent expansion, which strengthens the Company's SurgWerks™ and CellWerksTM product patent portfolio. Specifically, this patent allowance further protects our CLIRST III and AMIRST II trials as well as our bone marrow transplant program and their future U.S. commercial coverage."
Robin C. Stracey, Chief Executive Officer of Cesca Therapeutics added, "This patent also underscores the medical, scientific and technical progress our Company continues to make as evidenced by our June 16, 2015 announcement of the FDA IDE approval for a U.S. Pivotal Clinical Trial in Critical Limb Ischemia (CLIRST III) and our IEC/IRB Approval in India for our AMIRST II trial announced on May 20, 2015 for an ST-Evaluated Myocardial Infarction (STEMI)."
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:
- SurgWerks™; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:
- Cell harvesting
- Cell processing and selection
- Cell diagnostics
- Cell delivery
- CellWerksTM; a proprietary stem cell laboratory kit for the processing of target cells used in the treatment of oncological and hematological disorders.
- The AutoXpress® (AXP); a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
- The MarrowXpress® (MXP); a derivative product of the AXP and its accompanying disposable bag set, for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control optical sensors that volume-reduces blood from bone marrow to a user defined volume in 30 minutes while retaining over 90% of mononuclear cells (MNCs).
- The Res-Q™ 60 (Res-Q); a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates for bone marrow concentrate (BMC) and whole blood for platelet rich plasma (PRP).
- The BioArchive® System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.
Forward Looking Statement:
The statements contained herein may include statements of future expectations and other forward looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements, including our ability to initiate and prosecute the pivotal CLIRST III trial, our ability to obtain efficacy consistent with prior CLI studies, continued FDA approval, Medicare reimbursement approval, timing of the Company's future submission of IDE, PMA and/or Medicare reimbursement applications, or amendments to such applications, and outcomes from such submissions. Further, clinical trial outcomes are not predictable, and results may vary from the Company's expectations, including the start of any such clinical trials, patient follow up issues, and costs associated with such trials. Further description of other risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements. Contact: Cesca Therapeutics Inc. http://www.cescatherapeutics.com. Cesca may, at its discretion, choose to publish on-going interim notifications, requests for further information as received from the FDA, Medicare or equivalent foreign agencies, but as a general policy only makes announcements regarding material or significant information, such as filing of applications, approvals, initiation of studies, and conclusions.
CONTACT: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, ProActive Advisory Group + 1-646-863-6519, or ir@cescatherapeutics.com 